Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study

OBJECTIVES: Insulin degludec (IDeg)/insulin aspart (IAsp; IDegAsp) is a co-formulation of 70% IDeg and 30% IAsp. According to several randomized controlled trials, IDegAsp is effective and safe for patients with type 2 diabetes mellitus (T2DM). A subgroup analysis of the ARISE study was conducted to...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Mafauzy, Lim, Siang Chin, Mumtaz, Malik, Uppal, Shweta, Mukherjee, Deepak, Kassim, Mohamed Saiful Mohd, Sreedharan, Shalini, Doraiswamy, Amudha Murugan, Chong, Kuck Meng, Tat, Lu Yu, Nordin, Sudzilla Binti, Giek, Jeshen Lau Hui, Hussein, Zanariah, Kadir, Khalid Abdul, Lau, Bik Kui, Chan, Siew Pheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Journal of the ASEAN Federation of Endocrine Societies 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213167/
https://www.ncbi.nlm.nih.gov/pubmed/37252419
http://dx.doi.org/10.15605/jafes.038.01.12

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213167/
https://www.ncbi.nlm.nih.gov/pubmed/37252419
http://dx.doi.org/10.15605/jafes.038.01.12

Ejemplares similares